Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF
Details : C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore's AIR Study Interim Analysis Suggests that C21 Improves Lung Function in IPF Patients
Details : With these results, the company initiates the planning of AIR 2, a double-blind controlled phase 2 dose-finding study to confirm these results and accelerate the development of C21 in parallel to completing the AIR trial.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Orphan Reach
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore IPF Interim Data Selected as an Oral "Late-breaker" at the ERS Congress
Details : The AIR trial1 is an open label single arm phase 2 trial in treatment naïve IPF patients in which 100 mg of C21 (VP01) was administered twice daily for 24 weeks with an optional 12-week extension.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 17, 2022
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Orphan Reach
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study
Details : C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as ...
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study is a phase II, multi-center, open-label, single-arm trial investigating the safety, effect on lung function and pharmacokinetics of C21 in 60 subjects with IPF.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Robust Effects of VP01 in Human Idiopathic Pulmonary Fibrosis Lung Tissue
Details : Fresh human IPF lung tissue harvested from a patient during lung transplantation showed stable expression of the VP01 target, AT2R, and treatment with clinically relevant concentrations of VP01 caused a dose-dependent decrease of TGFb1.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2020
Lead Product(s) : Buloxibutid
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable